- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01841463
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
3. září 2014 aktualizováno: Piramal Enterprises Limited
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
- An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation
- The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation
Přehled studie
Postavení
Pozastaveno
Intervence / Léčba
Typ studie
Intervenční
Zápis (Očekávaný)
100
Fáze
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
California
-
South San Francisco, California, Spojené státy, 94115
- UCSF Medical Center at Mount Zion
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Anschutz Medical Campus
-
-
District of Columbia
-
Washington, District of Columbia, Spojené státy, 20057
- Georgetown-Lombardi Comprehensive Cancer Ctr
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- The University of Texas, MD Anderson Cancer Center
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Patients having histologically confirmed unresectable (Stage III) or metastatic (Stage IV) malignant melanoma with a positive BRAF mutation result determined by Roche CoDx or local CLIA-certified analysis
- Patients naïve to a selective BRAF inhibitor therapy or must have progressed after therapy on a selective BRAF inhibitor. For patients entering the protocol progressing on vemurafenib therapy, they must be tolerant of the 960 mg po bid dose.
- Tumor biopsies are optional in this study except for patients entering the mandatory biopsy cohorts. Nevertheless tumor biopsies are encouraged, especially in patients with accessible tumors for biopsy to include the collection of formalin-fixed, paraffin-embedded (FFPE) and fresh- frozen tissue (FF) as outlined in the biomarker sections of the protocol. Willingness of patient to give consent of biopsy, should be ascertained
- Patients of ≥ 18 years of age
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or1
- Patients with measurable disease per 'Response Evaluation Criteria In Solid Tumors' (RECIST version 1.1)
- Patients must have normal organ and adequate marrow function
- Patients with ability to swallow and retain oral medication
- Women of childbearing potential and men willing to agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the duration of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized.
- Negative serum pregnancy test within 10 days prior to commencement of therapy dosing in premenopausal women. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
Ability to understand and the willingness to offer a written Informed Consent document prior to the screening procedures for participation into the study
- For Extension phase-
- For patients entering the protocol progressing on vemurafenib therapy, they must be tolerant of the vemurafenib dose selected for the extension phase
Exclusion Criteria:
- Prior malignancy (within the last 2 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the patient has been disease-free for at least 2 years
- Patients who have received any prior chemotherapy, radiotherapy, biologic/targeted anti-cancer therapy (one week for BRAF inhibitor for melanoma) or surgery within 4 weeks (6 weeks for monoclonal antibodies, radioactive monoclonal antibodies or any radio-or toxin-immunoconjugates) before Day 1 of Investigational product administration and have not recovered (to < Grade 1) from the toxic effects from any prior therapy
- Patients having received any other investigational agents within 4 weeks prior to Day 1 of Investigational product administration and have not recovered completely (to < Grade 1) from the side effects of the earlier investigational agent
- Anticipated administration of any anti-cancer therapies (chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, surgery, and/or tumor embolisation) other than those administered in this study such as BRAF inhibitor
- Patients with symptomatic or untreated leptomeningeal or brain metastases, or spinal cord compression [patients with previous brain metastases will be allowed to enter the trial if metastases have been surgically removed or all known sites of metastases have been treated with stereotactic high dose radiosurgery. Patients must be off corticosteroids for at least one month and have a stable lesion with verification by imaging (CT/MRI) within 28 days prior to Day 1 of Investigational product administration]
- Patients with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic diarrheal condition, refractory nausea, vomiting or any other condition that will interfere significantly with the absorption of study drugs
- Patients with mean QTc interval >480 msec at screening
- Treatment with drugs with potential to cause dysrhythmias including but not limited to terfenadine, quinidine, procainamide, diisopyramide, sotalol, probucol, bepridil, haloperidol, risperidone and/or indapamide
- Patients on warfarin treatment
- Any condition for which participation in this study as judged by the Investigator to be detrimental to the patient with (such as) inter-current illness including, but not limited to ongoing or active infection, New York Heart Association functional classification class III, or IV heart failure; unstable angina pectoris; cardiac arrhythmia; history of myocardial infarction; uncontrolled hypertension (blood pressure above 160/100 mm Hg despite antihypertensive treatment); coronary artery bypass graft; cerebrovascular accident; transient ischemic attack or pulmonary embolism during the previous 6 months or psychiatric illness/social situations that would jeopardize compliance with study requirements
- Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to any other medication chemically related to P1446A-05 or vemurafenib, or excipients considered to be clinically significant by the investigator
- Nursing woman
- Patients with known HIV positivity or AIDS- related illness, or active Hepatitis B virus, and active Hepatitis C virus
- Patients taking drugs known to prolong the QTc interval who cannot be switched to an alternative drug.
For Extension phase-
- Patients with active second malignancy will be eligible as long as they do not need systemic therapy for the second malignancy
- Patients with active brain metastases will be included in the study as long as the tumor size is less than 1 cm without the requirement of steroid use for neurological symptoms
- Patients with evaluable metastatic disease will be allowed even if there is no measurable disease per RECIST 1.1. In this case patients with many sub centimeter in-transit skin/SQ nodules will be eligible for the biopsy cohort.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: P1446A-05
|
- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group.
The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined.
In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration.
Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Maximum Tolerated Dose and Dose Limiting Toxicity
Časové okno: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
The study will be conducted in two phases- Phase I (Dose escalation phase), and Extension phase.
In the Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group.
The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.
In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration.
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Tumor Response
Časové okno: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
- To determine best Overall Response Rate (ORR), Duration of response (DOR), Progression Free Survival (PFS), and Overall Survival (OS) of the co-administration of P1446A 05 and vemurafenib using RECIST version 1.1 in melanoma patients with BRAF mutation
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Pharmacokinetic (PK)
Časové okno: Cycle1 (Day 15 and 22) and Cycle 2 (Day1,15 and 28)
|
|
Cycle1 (Day 15 and 22) and Cycle 2 (Day1,15 and 28)
|
Biomarker Analysis
Časové okno: Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
|
Until disease progression or unacceptable toxicity (expected to be 6-8 months)
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Adil Daud, MD, UCSF Medical Center at Mount Zion
- Vrchní vyšetřovatel: Kevin B Kim, MD, The University of Texas MD Anderson Cancer Center
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. srpna 2013
Primární dokončení (Očekávaný)
1. března 2015
Dokončení studie (Očekávaný)
1. března 2016
Termíny zápisu do studia
První předloženo
17. dubna 2013
První předloženo, které splnilo kritéria kontroly kvality
23. dubna 2013
První zveřejněno (Odhad)
26. dubna 2013
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
4. září 2014
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
3. září 2014
Naposledy ověřeno
1. září 2014
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary podle histologického typu
- Novotvary
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Neuroendokrinní nádory
- Nevi a melanomy
- Melanom
- Molekulární mechanismy farmakologického působení
- Inhibitory enzymů
- Antineoplastická činidla
- Inhibitory proteinkinázy
- Vemurafenib
Další identifikační čísla studie
- P1446A-05/72/12
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na P1446A-05
-
Tarsus Pharmaceuticals, Inc.Dokončeno
-
Tarsus Pharmaceuticals, Inc.Aktivní, ne náborZdravý dobrovolníkSpojené státy
-
National Institute of Allergy and Infectious Diseases...Dokončeno
-
Cadila PharnmaceuticalsUkončenoStádium III nebo stadium IV melanomuSpojené státy
-
CuraGen CorporationDokončenoStomatitidaSpojené státy
-
Meridigen Biotech Co., Ltd.Nábor
-
Centrexion TherapeuticsDokončenoOsteoartróza, kolenoSpojené státy
-
Breath of Life International Pharma LtdStaženoDiabetes mellitus typu 1
-
CuraGen CorporationDokončenoStomatitida | Orální mukositidaSpojené státy
-
Tarsus Pharmaceuticals, Inc.Dokončeno